Chardan Capital reissued their buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a research note released on Wednesday morning,Benzinga reports. The firm currently has a $425.00 target price on the biopharmaceutical company’s stock. Other research analysts also recently issued reports about the company. Leerink Partners lowered their price target on Alnylam […]

Palvella Therapeutics (NASDAQ:PVLA – Get Free Report)‘s stock had its “buy” rating reissued by Chardan Capital in a report issued on Monday,Benzinga reports. They presently have a $210.00 price objective on the stock. Chardan Capital’s price objective points to a potential upside of 65.93% from the stock’s previous close. PVLA has been the topic of […]